Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 119 entries
View as:

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

Phase: N/A Priority: Normal
NCT ID: NCT03384212 Org: User:
Start: 08/01/16 End: 07/31/22 Due: 07/31/23

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

Phase: N/A Priority: Normal
NCT ID: NCT06509945 Org: User:
Start: 07/15/24 End: 07/15/26 Due: 07/15/27

Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06115733 Org: User:
Start: 12/28/23 End: 12/31/26 Due: 12/31/27

Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

Phase: N/A Priority: Normal
NCT ID: NCT06754540 Org: User:
Start: 01/16/25 End: 01/01/27 Due: 01/01/28

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Phase: N/A Priority: Normal
NCT ID: NCT06307054 Org: User:
Start: 03/15/24 End: 03/15/27 Due: 03/15/28

Modified Bortezomib-based Combination Therapy for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02559154 Org: User:
Start: 07/31/10 End: 12/31/18 Due: 12/31/19

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

Phase: N/A Priority: Normal
NCT ID: NCT05814952 Org: User:
Start: 12/13/22 End: 08/31/28 Due: 08/31/29

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

Phase: N/A Priority: Normal
NCT ID: NCT03384225 Org: User:
Start: 08/01/16 End: 07/31/22 Due: 07/31/23

Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT07003490 Org: User:
Start: 01/01/25 End: 08/01/27 Due: 08/01/28

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05290155 Org: User:
Start: 05/04/22 End: 05/01/25 Due: 05/01/26

The Pathogenesis of Human Senile Cataract

Phase: N/A Priority: Normal
NCT ID: NCT03907358 Org: User:
Start: 12/07/16 End: 06/30/20 Due: 06/30/21

Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Phase: N/A Priority: Normal
NCT ID: NCT04232397 Org: User:
Start: 04/10/20 End: 03/01/21 Due: 03/01/22

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05831033 Org: User:
Start: 05/23/23 End: 06/15/27 Due: 06/15/28

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Phase: N/A Priority: Normal
NCT ID: NCT06686108 Org: User:
Start: 10/30/24 End: 10/30/28 Due: 10/30/29

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT02634294 Org: User:
Start: 08/31/15 End: 12/31/21 Due: 12/31/22

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Phase: N/A Priority: Normal
NCT ID: NCT06024057 Org: User:
Start: 09/01/23 End: 09/30/38 Due: 09/30/39

Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL

Phase: N/A Priority: Normal
NCT ID: NCT05379569 Org: User:
Start: 05/15/22 End: 12/30/25 Due: 12/30/26

Evaluation of Vulnerability of Carotid Plaques and Prediction of Cardio-Cerebrovascular Event Using Ultrasonic Imaging

Phase: N/A Priority: Normal
NCT ID: NCT06473272 Org: User:
Start: 07/01/24 End: 12/31/27 Due: 12/31/28

Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT03395860 Org: User:
Start: 05/30/17 End: 12/20/21 Due: 12/20/22

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05576532 Org: User:
Start: 01/10/23 End: 10/10/25 Due: 10/10/26

Effect of Short-term Portable Air Purifier Use on Occupant Health Indicators

Phase: N/A Priority: Normal
NCT ID: NCT02736487 Org: User:
Start: 11/30/15 End: 12/31/15 Due: 12/31/16

Rapid Assessment of Donor Liver Quality

Phase: N/A Priority: Normal
NCT ID: NCT03647059 Org: User:
Start: 08/15/18 End: 08/15/22 Due: 08/15/23

Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06515587 Org: User:
Start: 08/01/24 End: 10/31/26 Due: 10/31/27

Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)

Phase: N/A Priority: Normal
NCT ID: NCT03264976 Org: User:
Start: 07/01/18 End: 07/01/23 Due: 07/01/24

Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC

Phase: N/A Priority: Normal
NCT ID: NCT02948985 Org: User:
Start: 01/31/17 End: 12/31/19 Due: 12/31/20